Alembic Pharmaceuticals is positioning its US business for 10-15% growth by FY27, driven by a strong pipeline with over 15 new product launches planned, including products for niche markets and complex generics targeting conditions like leukemia and hypertension. As reported by Moneycontrol, the company's US segment contributed ₹2,206 crore to FY26 revenue, representing a 30% share of total revenue. The US business demonstrated strong performance with 13% growth in FY26, supported by both pricing and volume improvements. The strategy aims to benefit from price increases and higher sales volumes in the US market, with Equirus analysts predicting mid-teen growth for the US market over the next two years. Amin noted that the momentum is being supported by consistent product launches and market share gains, with the company picking up share and launching products successfully.
Despite strong business fundamentals, Alembic's profitability remains under pressure with EBITDA margin falling to 12.3% in Q4, impacted by major upfront investments in the US branded business, pipeline development, new facilities, and higher R&D spending. According to Moneycontrol, Amin attributed the decline to front-loaded investments, particularly in the US branded business and pipeline building. The company expects margins to gradually recover to 20% EBITDA over the next two to three years, driven by scale benefits, better capacity utilisation, and high-value launches. However, analysts warn the US branded segment could lower margins by 100-150 basis points in FY27 before stabilising. The company's historical margin contraction shows PAT margins falling to 8.72% and operating margins to 15.11% by FY25, highlighting significant profitability challenges. Management expects margins to gradually recover to 20% in two to three years, driven by scale, better capacity use, and higher-margin complex products.
Beyond the US market, Alembic is leveraging a diversified portfolio for growth across multiple segments. As reported by Moneycontrol, the rest-of-world business achieved 20% growth in FY26 and is expected to sustain 15% growth, while the API segment continues steady, albeit modest, expansion. However, the India business remains a challenge with 4-5% domestic revenue growth, facing pressure in key therapy segments. The company's strategy now focuses on improving execution and utilising existing assets rather than fresh capital expenditure, with future spending largely limited to maintenance and R&D. Management is doubling down on complex generics, peptides and specialty therapies, which offer higher margins but require upfront investment. The global complex generics market is expected to reach $180-200 billion by 2032-2035, mirroring a wider industry trend of moving to higher-value products for better profits.
Alembic Pharmaceuticals' market value ranges between ₹14,138 crore and ₹15,441 crore, with a trailing twelve-month P/E ratio of 19.4 to 32.6. The company's P/E ratio is moderate compared to peers like Sun Pharma (34.7-41.0) and Cipla (28.4-29.9), while Dr. Reddy's Laboratories trades lower (17.3-26.9). The Nifty Pharma index trades at a P/E of 38.7. Despite positive outlook for US growth, Alembic's sales grew modestly at 6.37% over five years, contrasting with peers like Dr. Reddy's. Current analyst consensus targets of ₹940-₹991 suggest a potential 20-26% upside, though this optimism might not fully account for execution risks in reviving margins and ongoing large investments. The company's focus on complex generics could lead to higher margins, but large investments and long timelines for development carry significant risks.
